The amount of cash generated by global public and private biopharmaceutical companies was up significantly in the third quarter compared to the second quarter. The almost $16 billion haul was 45 percent higher than the $11 billion raised during the second quarter and almost 25 percent higher than the total generated in the same period last year. Thanks to their higher company valuations, public companies were able to conduct public offerings with confidence, and the amount of private capital raised ballooned to more than $3.23 billion – a 61 percent increase over the $2 billion generated in the second quarter of this year. Read More
Biopharmaceutical companies continue to enjoy a banner year, and the sector as a whole remains a favorite with investors, a fact confirmed by Jefferies analyst Michael Yee, who wrote that "the biotech sector [is] seeing an increase in money flow and better performance vs. the broader market and other health care sectors." Read More
